Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | NPY4R | P50391 | 14/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.45 |
| ▸ | NPY1R | P25929 | 8/20 | 0.45 |
| ▸ | NPY2R | P49146 | 5/20 | 0.45 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.41 |
| ▸ | MC4R | P32245 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7130279 | 0.88 | NPY4R (0.46) | CYP3A4CYP2C19NPY4RNPY5RNPY1R | |
| SCHEMBL7119582 | 0.85 | NPY4R (0.44) | CYP3A4CYP2C19NPY4RNPY5RNPY1R | |
| SCHEMBL7116399 | 0.85 | NPY4R (0.48) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL7115453 | 0.83 | BMP1 (0.55) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL7116210 | 0.82 | NPY4R (0.49) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL7122955 | 0.82 | NPY4R (0.46) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL7117030 | 0.81 | KCNA5 (0.49) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL7131237 | 0.81 | PSMB5 (0.47) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL7132417 | 0.81 | NPY4R (0.45) | NPY4RNPY5RNPY1RNPY2RKISS1R | |
| SCHEMBL7117572 | 0.80 | NPY4R (0.44) | NPY4RNPY5RNPY1RNPY2RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | H. LUNDBECK A/S (DK) | 2003-09-18 | — | — | US | disclosed |
| US-20030144310-A1 | Molecules specific for NPFF receptors and uses thereof | H. LUNDBECK A/S (DK) | 2003-07-31 | — | — | US | disclosed |
| WO-2003026657-A1 | COMPOUNDS FOR THE TREATMENT OF PAIN | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
| WO-2003026575-A2 | MOLECULES SPECIFIC FOR NPFF RECEPTORS AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030176314-A1 | Compounds for the treatment of pain | NPFFR2, NPFFR1, OPRL1 | CYP3A4 4583/4885CYP2C19 4185/4885NPY4R 137/4885 |
| US-20030144310-A1 | Molecules specific for NPFF receptors and uses thereof | NPFFR1, NPFFR2, NPBWR1 | CYP3A4 3693/4885CYP2C19 4633/4885NPY4R 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.